Korea Investment Partners (KIP) is a leading Asian venture capital firm. Founded in Seoul, South Korea, in 1986, it has maintained a steady investment pace and grown into an Asia-based firm with investments across global markets. KIP's portfolio spans Asia, Europe and the Americas, with investments in more than 1,000 companies worldwide. More than 300 have listed on public markets in different countries and regions, and cumulative assets under management exceed US$5 billion. KIP entered China in 2008 and has offices in Shanghai, Beijing, Guangzhou, Shenzhen and Chengdu. It has established multiple renminbi funds totaling more than RMB3 billion. The firm has invested in dozens of industry-leading companies in advanced technology, enterprise services, healthcare and consumer sectors. Representative investments include Henlius (02696.HK), Weimob (02013.HK), DiDi (DIDI.US), Boqii (BQ.US), Wanka Online (01762.HK), Ascentage Pharma (06855.HK), Peijia Medical (09996.HK), Kawin Technology (688607.SH), NewLink Group (NASDAQ: NAAS), geoskincare, Quanyuantang, Duolabao, Gaussian Robotics and Kelala.
Website: www.kipvc.cn
From the original English profile
The English-language profile included these additional details.
KIP was described as an affiliate of Korea Investment Holdings, investing through both venture capital and private equity in early-stage and growth-stage companies. It also supported portfolio companies with business operations and international expansion.